Standard Lithium (NYSE:SLI – Get Free Report) and BioLargo (NASDAQ:BLGO – Get Free Report) are both small-cap oils/energy companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.
Earnings & Valuation
This table compares Standard Lithium and BioLargo”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Standard Lithium | N/A | N/A | $108.82 million | $0.59 | 2.75 |
BioLargo | $12.23 million | 6.21 | -$3.50 million | ($0.01) | -25.22 |
Standard Lithium has higher earnings, but lower revenue than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than Standard Lithium, indicating that it is currently the more affordable of the two stocks.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Standard Lithium | N/A | -11.52% | -10.25% |
BioLargo | -11.45% | -39.90% | -22.06% |
Institutional and Insider Ownership
16.8% of Standard Lithium shares are held by institutional investors. Comparatively, 0.0% of BioLargo shares are held by institutional investors. 3.7% of Standard Lithium shares are held by company insiders. Comparatively, 20.3% of BioLargo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Standard Lithium has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, BioLargo has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Standard Lithium and BioLargo, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Standard Lithium | 0 | 0 | 2 | 0 | 3.00 |
BioLargo | 0 | 0 | 0 | 0 | 0.00 |
Standard Lithium presently has a consensus price target of $3.95, indicating a potential upside of 143.83%. Given Standard Lithium’s stronger consensus rating and higher possible upside, analysts clearly believe Standard Lithium is more favorable than BioLargo.
Summary
Standard Lithium beats BioLargo on 11 of the 13 factors compared between the two stocks.
About Standard Lithium
Standard Lithium Ltd. explores for, develops, and processes lithium brine properties in the United States. Its flagship project is the Lanxess project with area of approximately 150,000 acres located in southern Arkansas. The company was formerly known as Patriot Petroleum Corp. and changed its name to Standard Lithium Ltd. in December 2016. Standard Lithium Ltd. was incorporated in 1998 and is headquartered in Vancouver, Canada.
About BioLargo
BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.
Receive News & Ratings for Standard Lithium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Standard Lithium and related companies with MarketBeat.com's FREE daily email newsletter.